GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
You may also be interested in...
GSK Approval Plan For COX-2 Inhibitor Includes Lower Doses In Phase III
The company will experiment with lower doses of its COX-2 inhibitor, 406381, to mitigate the cardiovascular risk seen with the class, CEO Garnier says. While FDA has “blessed” GSK’s Phase III program, testing multiple doses will give GSK “more chances to win.” The agency is also asking for a cardiovascular safety study.
GSK Approval Plan For COX-2 Inhibitor Includes Lower Doses In Phase III
The company will experiment with lower doses of its COX-2 inhibitor, 406381, to mitigate the cardiovascular risk seen with the class, CEO Garnier says. While FDA has “blessed” GSK’s Phase III program, testing multiple doses will give GSK “more chances to win.” The agency is also asking for a cardiovascular safety study.
Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.